Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Frontiers
Research related to COVID-19
Vaccine Basics
Joint Research Coronavirus Task Force Established to Promote Research
Covid: First round of US vaccinations to begin on Monday • News784
COMMENTS
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Here, we report safety and efficacy findings from the phase 2/3 part of a global phase 1/2/3 trial evaluating the safety, immunogenicity, and efficacy of 30 μg of BNT162b2 in preventing Covid-19 ...
Long-term effectiveness of COVID-19 vaccines against infections
Our analyses indicate that vaccine effectiveness generally decreases over time against SARS-CoV-2 infections, hospitalisations, and mortality. The baseline vaccine effectiveness levels for the omicron variant were notably lower than for other variants. Therefore, other preventive measures (eg, face-mask wearing and physical distancing) might be necessary to manage the pandemic in the long term.
Inside the story about the research and development of COVID-19 vaccines
1. Safety and immunogenicity study of 2019-nCoV vaccine (mRNA-1273) for prophylaxis of SARS-CoV-2 infection (COVID-19) This clinical trial is designed to assess the safety, reactogenicity, and immunogenicity of mRNA-1273. It encodes for a full-length, prefusion stabilized spike (S) protein of SARS-CoV-2.
Comprehensive literature review on COVID-19 vaccines and role of SARS
Introduction. The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in over 192 million cases and 4.1 million deaths as of July 22, 2021. 1 This pandemic has brought along a massive burden in morbidity and mortality in the healthcare systems. Despite the implementation of stringent public health measures, there ...
Effectiveness of COVID‐19 vaccines: findings from real world studies
In the UK, over 600 000 volunteers using a COVID‐19 symptom mobile phone app recorded adverse events after vaccination with either the Pfizer-BioNTech or Oxford-AstraZeneca vaccine. 11 Based on post‐vaccination self‐reports of infections and after adjustment for age, sex, obesity and comorbidities, they estimated effectiveness rates ...
Comparing the clinical efficacy of COVID-19 vaccines: a ...
No vaccine was statistically significantly associated with a decreased risk for severe COVID-19 than other vaccines, although mRNA-1273 and Gam-COVID-Vac have the highest P-scores (0.899 and 0.816 ...
COVID-19 Vaccines
By the end of November 2021, scientists estimate that mRNA COVID-19 vaccines had prevented at least 1 million deaths, 10 million hospitalizations, and 36 million SARS-CoV-2 infections in the United States. Sometimes people who are fully vaccinated get a breakthrough infection, meaning that they test positive for SARS-CoV-2 or become ill with ...
Peer-reviewed report on Moderna COVID-19 vaccine publishes
The investigational vaccine known as mRNA-1273 was 94.1% efficacious in preventing symptomatic coronavirus disease 2019 (COVID-19), according to preliminary results from a Phase 3 clinical trial reported in the New England Journal of Medicine. The vaccine also demonstrated efficacy in preventing severe COVID-19.
COVID vaccines and safety: what the research says
There is no question that the current vaccines are effective and safe. The risk of severe reaction to a COVID-19 jab, say researchers, is outweighed by the protection it offers against the deadly ...
SARS-CoV-2 vaccines strategies: a comprehensive review of ...
The new SARS-CoV-2 virus is an RNA virus that belongs to the Coronaviridae family and causes COVID-19 disease. The newly sequenced virus appears to originate in China and rapidly spread throughout ...
Oxford-AstraZeneca COVID-19 vaccine efficacy
This is the first report of efficacy against COVID-19 for a non-profit vaccine aiming for global supply, equity, and commitment to low-income and middle-income countries (LMICs), and as such its publication is very welcomed. After phase 1 results supported a two-dose regimen, the trial protocols were amended where necessary to require two ...
Coronavirus disease (COVID-19): Vaccine research and development
Now, given the urgent need for COVID-19 vaccines, unprecedented financial investments and scientific collaborations are changing how vaccines are developed. This means that some of the steps in the research and development process have been happening in parallel, while still maintaining strict clinical and safety standards.
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
To the Editor: Polack et al. (Dec. 31) 1 report a vaccine efficacy of 94.8% against Covid-19 after two doses of the messenger RNA (mRNA) vaccine BNT162b2 (Pfizer-BioNTech). The authors also ...
COVID-19 vaccine waning and effectiveness and side-effects of boosters
The effectiveness against infection of COVID-19 vaccines waned considerably 5-8 months after primary vaccination, although it remained high, particularly among people younger than 55 years. ... participants provide consent for their data to be used in COVID-19 research. They self-report demographic characteristics including age, sex, body ...
COVID-19 Vaccine: A comprehensive status report
2. Vaccination strategies. Many efforts have been directed towards the development of the vaccines against COVID-19, to avert the pandemic and most of the developing vaccine candidates have been using the S-protein of SARS-CoV-2 (Dhama et al., 2020).As of July 2, 2020, the worldwide SARS-CoV-2 vaccine landscape includes 158 vaccine candidates, out of which 135 are in the preclinical or the ...
COVID-19 Vaccine: A comprehensive status report
Abstract. The current COVID-19 pandemic has urged the scientific community internationally to find answers in terms of therapeutics and vaccines to control SARS-CoV-2. Published investigations mostly on SARS-CoV and to some extent on MERS has taught lessons on vaccination strategies to this novel coronavirus. This is attributed to the fact that ...
COVID-19 Vaccine Focused on T-Cell Response Promising in Early Trial
Investigators reported the first clinical trial results for CoVac-1, a COVID-19 vaccine candidate designed to induce T-cell immunity, in Nature.The multipeptide-based vaccine had a favorable safety profile and induced a broad and potent T-cell response. Developed at the University of Tübingen in Germany, CoVac-1 is an adjuvanted vaccine candidate that includes 6 SARS-CoV-2 peptides recognized ...
Repeat COVID-19 vaccinations elicit antibodies that ...
A study has found that repeat vaccination with updated versions of the COVID-19 vaccine promotes the development of antibodies that neutralize a wide range of variants of the virus that causes ...
Post-COVID conditions following COVID-19 vaccination: a ...
S.Y.T. reports research support from Pfizer paid directly to institution for COVID-19 vaccine effectiveness and Paxlovid studies. C.C.F. reports research support from Pfizer and Johnson & Johnson ...
Evolving With the Virus: Repeat COVID-19 Shots ...
Healthcare workers received the first doses of the COVID-19 vaccine in December 2020. A study by researchers at Washington University School of Medicine in St. Louis has found that repeat vaccination with updated versions of the COVID-19 vaccine promotes the development of antibodies that neutralize a wide range of variants of the virus that causes COVID-19, as well as related coronaviruses.
Evaluating COVID-19 vaccines in the real world
The effectiveness of the mRNA vaccines in preventing COVID-19 disease progression in 2021 set new expectations about the role of prevention interventions for the disease. Efficacy observed in the trials was more than 90%.1,2 The efficacy of other vaccines evaluated in large randomised trials, such as the Oxford-AstraZeneca (70%) and Sputnik V (91%) vaccines, have been criticised for elements ...
Study reveals positive impact of repeat COVID-19 vaccinations
Health-care workers received the first doses of the COVID-19 vaccine in December 2020. A study by researchers at Washington University School of Medicine in St. Louis has found that repeat ...
Efficacy of COVID-19 vaccines: From clinical trials to real life
Despite questions remain about the impact of virus variants and the duration of the immune response, messenger RNA (mRNA)-based and adenoviral vectored vaccines have demonstrated an overall efficacy from 70 to 95% in both phase III trials and real life. In addition, all these vaccines also reduce the severe forms of the disease and might ...
COVID vaccines could protect against other outbreaks: study
A group of researchers had the future in mind when they asked if current COVID-19 vaccines and boosters could also protect your body against future outbreaks in a study published in the journal ...
Variants of the Virus
Monitoring Variants. CDC uses viral genomic surveillance to quickly identify and track COVID-19 variants, and acts upon these findings to protect the public's health.Some variants spread more easily and quickly than others, which may lead to more cases of COVID-19. For the most up to date information about current variants, visit CDC's COVID Data Tracker.
Voices for health: driving universal health coverage through social
As demonstrated during the COVID-19 crisis, the lack of these aforementioned conditions contributed to low compliance with public health guidelines, slow vaccine uptake and negative health outcomes.Robust health systems demand strong governance; otherwise progress towards UHC risks stagnating or even reversing. ... 2023 Global Monitoring Report ...
COVID-19 vaccines: Current evidence and considerations
There's no report so far that the COVID-19 vaccine can prevent transmission, but it can help protect against COVID-19 infection. ... strong collaboration among the research centers, sufficient funding, and the urgent/huge market demand. Since the beginning of the COVID-19 pandemic, many countries are competing to develop vaccines. The ...
IMAGES
COMMENTS
Here, we report safety and efficacy findings from the phase 2/3 part of a global phase 1/2/3 trial evaluating the safety, immunogenicity, and efficacy of 30 μg of BNT162b2 in preventing Covid-19 ...
Our analyses indicate that vaccine effectiveness generally decreases over time against SARS-CoV-2 infections, hospitalisations, and mortality. The baseline vaccine effectiveness levels for the omicron variant were notably lower than for other variants. Therefore, other preventive measures (eg, face-mask wearing and physical distancing) might be necessary to manage the pandemic in the long term.
1. Safety and immunogenicity study of 2019-nCoV vaccine (mRNA-1273) for prophylaxis of SARS-CoV-2 infection (COVID-19) This clinical trial is designed to assess the safety, reactogenicity, and immunogenicity of mRNA-1273. It encodes for a full-length, prefusion stabilized spike (S) protein of SARS-CoV-2.
Introduction. The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in over 192 million cases and 4.1 million deaths as of July 22, 2021. 1 This pandemic has brought along a massive burden in morbidity and mortality in the healthcare systems. Despite the implementation of stringent public health measures, there ...
In the UK, over 600 000 volunteers using a COVID‐19 symptom mobile phone app recorded adverse events after vaccination with either the Pfizer-BioNTech or Oxford-AstraZeneca vaccine. 11 Based on post‐vaccination self‐reports of infections and after adjustment for age, sex, obesity and comorbidities, they estimated effectiveness rates ...
No vaccine was statistically significantly associated with a decreased risk for severe COVID-19 than other vaccines, although mRNA-1273 and Gam-COVID-Vac have the highest P-scores (0.899 and 0.816 ...
By the end of November 2021, scientists estimate that mRNA COVID-19 vaccines had prevented at least 1 million deaths, 10 million hospitalizations, and 36 million SARS-CoV-2 infections in the United States. Sometimes people who are fully vaccinated get a breakthrough infection, meaning that they test positive for SARS-CoV-2 or become ill with ...
The investigational vaccine known as mRNA-1273 was 94.1% efficacious in preventing symptomatic coronavirus disease 2019 (COVID-19), according to preliminary results from a Phase 3 clinical trial reported in the New England Journal of Medicine. The vaccine also demonstrated efficacy in preventing severe COVID-19.
There is no question that the current vaccines are effective and safe. The risk of severe reaction to a COVID-19 jab, say researchers, is outweighed by the protection it offers against the deadly ...
The new SARS-CoV-2 virus is an RNA virus that belongs to the Coronaviridae family and causes COVID-19 disease. The newly sequenced virus appears to originate in China and rapidly spread throughout ...
This is the first report of efficacy against COVID-19 for a non-profit vaccine aiming for global supply, equity, and commitment to low-income and middle-income countries (LMICs), and as such its publication is very welcomed. After phase 1 results supported a two-dose regimen, the trial protocols were amended where necessary to require two ...
Now, given the urgent need for COVID-19 vaccines, unprecedented financial investments and scientific collaborations are changing how vaccines are developed. This means that some of the steps in the research and development process have been happening in parallel, while still maintaining strict clinical and safety standards.
To the Editor: Polack et al. (Dec. 31) 1 report a vaccine efficacy of 94.8% against Covid-19 after two doses of the messenger RNA (mRNA) vaccine BNT162b2 (Pfizer-BioNTech). The authors also ...
The effectiveness against infection of COVID-19 vaccines waned considerably 5-8 months after primary vaccination, although it remained high, particularly among people younger than 55 years. ... participants provide consent for their data to be used in COVID-19 research. They self-report demographic characteristics including age, sex, body ...
2. Vaccination strategies. Many efforts have been directed towards the development of the vaccines against COVID-19, to avert the pandemic and most of the developing vaccine candidates have been using the S-protein of SARS-CoV-2 (Dhama et al., 2020).As of July 2, 2020, the worldwide SARS-CoV-2 vaccine landscape includes 158 vaccine candidates, out of which 135 are in the preclinical or the ...
Abstract. The current COVID-19 pandemic has urged the scientific community internationally to find answers in terms of therapeutics and vaccines to control SARS-CoV-2. Published investigations mostly on SARS-CoV and to some extent on MERS has taught lessons on vaccination strategies to this novel coronavirus. This is attributed to the fact that ...
Investigators reported the first clinical trial results for CoVac-1, a COVID-19 vaccine candidate designed to induce T-cell immunity, in Nature.The multipeptide-based vaccine had a favorable safety profile and induced a broad and potent T-cell response. Developed at the University of Tübingen in Germany, CoVac-1 is an adjuvanted vaccine candidate that includes 6 SARS-CoV-2 peptides recognized ...
A study has found that repeat vaccination with updated versions of the COVID-19 vaccine promotes the development of antibodies that neutralize a wide range of variants of the virus that causes ...
S.Y.T. reports research support from Pfizer paid directly to institution for COVID-19 vaccine effectiveness and Paxlovid studies. C.C.F. reports research support from Pfizer and Johnson & Johnson ...
Healthcare workers received the first doses of the COVID-19 vaccine in December 2020. A study by researchers at Washington University School of Medicine in St. Louis has found that repeat vaccination with updated versions of the COVID-19 vaccine promotes the development of antibodies that neutralize a wide range of variants of the virus that causes COVID-19, as well as related coronaviruses.
The effectiveness of the mRNA vaccines in preventing COVID-19 disease progression in 2021 set new expectations about the role of prevention interventions for the disease. Efficacy observed in the trials was more than 90%.1,2 The efficacy of other vaccines evaluated in large randomised trials, such as the Oxford-AstraZeneca (70%) and Sputnik V (91%) vaccines, have been criticised for elements ...
Health-care workers received the first doses of the COVID-19 vaccine in December 2020. A study by researchers at Washington University School of Medicine in St. Louis has found that repeat ...
Despite questions remain about the impact of virus variants and the duration of the immune response, messenger RNA (mRNA)-based and adenoviral vectored vaccines have demonstrated an overall efficacy from 70 to 95% in both phase III trials and real life. In addition, all these vaccines also reduce the severe forms of the disease and might ...
A group of researchers had the future in mind when they asked if current COVID-19 vaccines and boosters could also protect your body against future outbreaks in a study published in the journal ...
Monitoring Variants. CDC uses viral genomic surveillance to quickly identify and track COVID-19 variants, and acts upon these findings to protect the public's health.Some variants spread more easily and quickly than others, which may lead to more cases of COVID-19. For the most up to date information about current variants, visit CDC's COVID Data Tracker.
As demonstrated during the COVID-19 crisis, the lack of these aforementioned conditions contributed to low compliance with public health guidelines, slow vaccine uptake and negative health outcomes.Robust health systems demand strong governance; otherwise progress towards UHC risks stagnating or even reversing. ... 2023 Global Monitoring Report ...
There's no report so far that the COVID-19 vaccine can prevent transmission, but it can help protect against COVID-19 infection. ... strong collaboration among the research centers, sufficient funding, and the urgent/huge market demand. Since the beginning of the COVID-19 pandemic, many countries are competing to develop vaccines. The ...